IDXX insider trading
NasdaqGS HealthcareIDEXX LABORATORIES INC /DE — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About IDEXX LABORATORIES INC /DE
IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. The company offers point-of-care diagnostic solutions, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology/morphology, and coagulation analyzers; and SNAP rapid assays test kits. It also provides commercial reference laboratory diagnostic and consulting services to veterinarians; veterinary consultation, telemedicine, and advisory services, including radiology, dental radiography, cardiology, internal medicine, and ultrasound consulting; Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, Quanti-Tray products, and Tecta system instruments; UV Viewer Plus, a UV light cabinet which aids in the visual interpretation of fluorescent-based water tests; and veterinary software and services for independent veterinary clinics and corporate groups. In addition, the company offers diagnostic tests, services, and related instrumentation to manage the health status of livestock and poultry; human medical diagnostic products and services; and VetConnect PLUS, a cloud-based technology that enables veterinarians to access and analyze patients, as well as operates VetLab Station. It markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
Company website: www.idexx.com
IDXX insider activity at a glance
FilingIQ has scored 1,802 insider transactions for IDXX since Aug 7, 2014. The most recent filing in our index is dated May 12, 2026.
Across the full history, 7 open-market purchases
and 660 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on IDXX insider trades is 64.0/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest IDXX Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
13F funds holding IDXX
Politicians who have traded IDXX
Frequently asked
- How many insider trades does FilingIQ track for IDXX?
- FilingIQ tracks 1,802 Form 4 insider transactions for IDXX (IDEXX LABORATORIES INC /DE), covering filings from Aug 7, 2014 onwards. 80 of those were filed in the last 90 days.
- Are IDXX insiders net buyers or net sellers?
- Across the full Form 4 history for IDXX, 7 transactions (0%) were open-market purchases and 660 (37%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does IDXX insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is IDXX in?
- IDEXX LABORATORIES INC /DE (IDXX) is classified in the Healthcare sector, specifically Diagnostics & Research, with a current market capitalisation of $50.61B.
Methodology & sources
Every IDXX insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.